This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deas, J. E.
Right arrow Articles by Gallaher, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deas, J. E.
Right arrow Articles by Gallaher, W. R.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, March 1998, p. 181-185, Vol. 5, No. 2
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Reactivity of Sera from Systemic Lupus Erythematosus and Sjögren's Syndrome Patients with Peptides Derived from Human Immunodeficiency Virus p24 Capsid Antigen

Jane E. Deas,1,* Leonita G. Liu,1 James J. Thompson,1 David M. Sander,2 Sara S. Soble,2 Robert F. Garry,2 and William R. Gallaher1,3

Department of Microbiology, Immunology and Parasitology1 and Stanley S. Scott Cancer Center,3 Louisiana State University Medical Center, and Department of Microbiology and Immunology, Tulane Medical Center,2 New Orleans, Louisiana 70112

Received 23 June 1997/Returned for modification 6 November 1997/Accepted 31 December 1997

We have previously demonstrated that about one-third of patients with either Sjögren's syndrome (SS) or systemic lupus erythematosus (SLE) react to human immunodeficiency virus (HIV) p24 core protein antigen without any evidence of exposure to, or infection with, HIV itself. Herein, we further characterize the specificity of this reaction using enzyme-linked immunosorbent assay to peptides representing fragments of p24. Characteristic epitope-specific profiles were seen for SS and SLE patients. SS patients had significantly increased responses to peptides F (p24 amino acids 69 to 86) and H (amino acids 101 to 111) and diminished reactivity to peptides A (amino acids 1 to 16) and P (amino acids 214 to 228). SLE patients had increased reactivity to peptides E (amino acids 61 to 76), H, and P. Utilization of peptide P hyporeactivity as the criterion to select for SS patients results in a screen that is moderately sensitive (64%) and specific (79.3%). Adding hyperreactivity to one other peptide (F or H) as an additional criterion yields an expected decrease in sensitivity (to 41%) while increasing specificity (to 93.1%). All sera-reactive peptides from regions of known structure of HIV p24 were located in the apex of the p24 molecule. Thus, the specificity of the peptide reactivities described here indicates a specific pattern of a nonrandom cross-reactivity between HIV type 1 p24 and autoimmune sera which may be partially syndrome specific. The future focus of our work will be to optimize assays of the peptide as diagnostic tools.


* Corresponding author. Mailing address: Department of Microbiology, Immunology and Parasitology, 1901 Perdido St., Box P6-1, New Orleans, LA 70112-1393. Phone: (504) 568-6116. Fax: (504) 568-2918. E-mail: WGALLA{at}LSUMC.edu.


Clinical and Diagnostic Laboratory Immunology, March 1998, p. 181-185, Vol. 5, No. 2
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.